logo
Bread Sold in 6 States Recalled Due to Glass Contamination

Bread Sold in 6 States Recalled Due to Glass Contamination

Epoch Times02-05-2025
A Glenn Dale, Maryland-based company has voluntarily recalled three types of its frozen bread products that had been distributed across six states.
The loaves were recalled due to glass contamination.
Upper Crust Crest Hill Bakery, also known as Upper Crust Bakery LP, announced on April 12 that it was recalling 89 cases of its 4-ounce Ancient Grains Hoagie Roll (Lot No. 90), 699 cases of its 18-ounce Multigrain Sourdough (Lot no. 90), and 30 cases of its 20-ounce Whole Grain Multigrain product (Lot no. 92), according to an FDA
The enforcement report shows that the products were distributed to retailers or wholesalers in Pennsylvania, California, Connecticut, Maryland, Delaware, and Ohio.
'Glass contamination can happen at several stages of food production due to equipment breakage, packaging accidents, and inadequate cleanup,' Darin Detwiler, a Northeastern University professor, food safety expert, and Alliance for Recall Ready Communities adviser, said in an email to NTD, a sister media outlet of The Epoch Times. 'This risk is why food facilities have strict policies called Glass and Brittle Plastic Control Programs—but lapses can still happen.'
Specifically, glass fragments were found on top of the three bread products. Neither the FDA nor the Upper Crust Crest Hill Bakery responded to requests for comment by press time.
Related Story
5/1/2025
The company says on its website that it partially bakes, then freezes, bread and pizza dough made with non-genetically modified ingredients. The products are then sold to wholesalers and food retailers.
The recall was initiated on April 12 and classified as a Class II recall by the FDA on April 25. The weekly enforcement report was published on April 30.
'The gap reflects the time needed for the FDA to review company data, assess risk, and assign a classification,' Detwiler said. 'The recall was not enforced late—it was logged into the weekly reporting system after classification.'
The recall was classified as a Class 2 event, which the FDA
Class 2 indicates a moderate risk to consumers, Detwiler said, while Class 1 indicates a higher risk level.
'What stands out here is the specific location of the hazard, which was on top of the bread,' he said.
'If this contamination was external and visible, it changes how the risk is perceived. It may also explain the Class II designation rather than a Class I, which is more typical for glass recalls.
'Identifying which lots went to which stores takes time and coordination, and more retail partners means more consumer alerts and more room for error,' Detwiler said. 'When recalled products appear under multiple store names, public confusion and brand damage can multiply.'
From NTD News
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Me-Too Cancer Drugs Not Often Compared to Original
Me-Too Cancer Drugs Not Often Compared to Original

Medscape

timean hour ago

  • Medscape

Me-Too Cancer Drugs Not Often Compared to Original

TOPLINE: In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their first-in-class counterparts. And in these head-to-head RCTs, only 22% of the 'me-too' agents showed a survival benefit compared to the originals. METHODOLOGY: Next-in-class, or 'me-too,' oncology drugs may theoretically offer improved efficacy, safety, or broader indications, yet little is known about how often RCTs directly compare these me-too agents with first-in-class drugs, leaving their true therapeutic value uncertain. Researchers looked at all 332 FDA approvals for anticancer drugs between 2009 and 2020. After excluding supportive care treatments, biosimilars, and drugs with novel routes of administration, 94 RCTs for me-too agents that received FDA approvals were included. The researchers then identified which next-in-class drugs had RCTs comparing them with their first-in-class counterparts, both at and after approval. Among RCTs with head-to-head comparison, primary endpoints varied across trials, with 63% using progression-free survival, 11% using overall survival, and 11% using response rate as their primary endpoint; 77.8% of trials were designed as superiority trials. TAKEAWAY: Only 27 RCTs that led to FDA approvals for me-too drugs — just under 29% — directly compared the new agent to the first-in-class drug (23 regular approvals and four accelerated approvals). Of these 27 RCTs, 12 trials were published at the time of FDA approval and 15 were published after approval. The median time to publication of post-approval trials was 2.8 years for regular approvals and 3.3 years for accelerated approvals. Overall, only six of the 27 trials (22.2%) demonstrated survival benefits, 14 trials (51.9%) met nonsurvival primary endpoints, and six trials (22.2%) failed to meet their primary endpoints. One trial is still ongoing. Among regular approvals designed as superiority trials, only 11 of 17 (64.7%) met their endpoints. Among accelerated approvals designed as superiority trials, three of four achieved their primary endpoints. The remaining six trials were not designed as superiority trials but met their primary endpoints. IN PRACTICE: 'These results suggest a need for regulatory bodies to incentivize within-class RCTs,' the authors wrote, adding that 'in cases where head-to-head RCTs were lacking, it is difficult to assess the true therapeutic value of next-in-class drugs.' SOURCE: This study, led by Timothée Olivier, MD, Geneva University Hospital, Geneva, Switzerland, was published online in JAMA Internal Medicine. LIMITATIONS: Drug development often occurred in parallel, limiting the feasibility of head-to-head comparisons. Some comparative trials published after the analysis period may not have been captured. DISCLOSURES: This project received funding from Arnold Ventures through a grant to the University of California San Francisco. One author reported receiving grants from Arnold Ventures and personal fees from John Hopkins University Press, MedPage, The Free Press, UnitedHealthcare, and other sources, outside the submitted work. Another author disclosed receiving honoraria from MashupMD and Medscape and research funding for his institution from Janssen, outside the submitted work. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use
Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use

Business Insider

time2 hours ago

  • Business Insider

Sarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy Use

Shares of Sarepta Therapeutics (SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments of its gene therapy for certain Duchenne muscular dystrophy (DMD) patients. SRPT stock has recovered some of its recent losses but remains down over 80% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. FDA Reversal Brings Relief for Sarepta On Monday, the FDA recommended partially lifting the hold on Elevidys shipments. The FDA had used a few rare deaths in patients with advanced DMD as a reason to reconsider the drug's approval and potentially remove it from the market. Now, the agency states that boys who can still walk independently are eligible to receive the gene therapy. This decision aligns with the existing evidence showing the treatment's benefits outweigh the risks. Back in June, the company had paused the use of the therapy in boys who could no longer walk while it investigated the safety concerns. Recently, SRPT stock dropped sharply after the FDA asked Sarepta to stop all Elevidys shipments. The decision came after the therapy was linked to two patient deaths, raising safety concerns. In response, the company voluntarily paused U.S. shipments of the treatment. For context, Elevidys is a one-time gene therapy for DMD in patients aged four and older, and it makes up about half of Sarepta's total revenue. What Is the Price Prediction for SRPT? According to TipRanks, Wall Street has a Hold consensus rating on SRPT stock, based on five Buys, 19 Holds, and five Sells assigned in the last three months. The average Sarepta Therapeutics stock price target of $21.68 implies a 37% upside potential.

UCSF's Vinay Prasad quits FDA under pressure from Trump allies
UCSF's Vinay Prasad quits FDA under pressure from Trump allies

San Francisco Chronicle​

time3 hours ago

  • San Francisco Chronicle​

UCSF's Vinay Prasad quits FDA under pressure from Trump allies

Dr. Vinay Prasad, a prominent UCSF oncologist and outspoken critic of the U.S. government's past pandemic policies, has resigned from his senior post at the Food and Drug Administration less than three months after assuming it. 'Dr. Prasad did not want to be a distraction to the great work of the FDA in the Trump administration and has decided to return to California and spend more time with his family,' said a spokesperson for the Department of Health and Human Services on Tuesday. Prasad was appointed in May to lead the FDA's Center for Biologics Evaluation and Research, overseeing vaccines and gene therapies. He was later named the agency's chief medical and scientific officer. Known for his sharp critiques of federal health policies and drug approvals, Prasad's appointment immediately raised concerns among biotech stakeholders. His sudden exit followed mounting political pressure, including a sustained campaign led by right-wing commentator Laura Loomer, who accused him of being a ' progressive leftist saboteur.' Loomer's criticism focused on Prasad's past podcast episodes and social media activity, where he expressed skepticism of President Donald Trump. Former Sen. Rick Santorum also joined the fray, calling Prasad the man who is destroying the president's 'legacy for helping patients.' Prasad had previously criticized the FDA's 2023 approval of Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy. This month, the FDA briefly suspended shipments of the drug following a patient death, only to partially reverse the decision a day before Prasad's resignation. Defending his colleague days before the resignation, FDA Commissioner Dr. Marty Makary described Prasad as 'one of the greatest scientific minds of our generation.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store